Lushuai

Shuai Lu obtained his Ph.D. degree in Medicinal Chemistry from China Pharmaceutical University under the supervision of Professor Tao Lu in 2012. He worked at the ITDD of University of Minnesota as a visiting scholar under the supervision of Dr. Gunda I. Georg from 2016 to 2017. Currently, he is an associate professor at China Pharmaceutical University. He is specialized in discovering new molecules targeting tumor, inflammation and other diseases by integrating molecular simulation, synthesis and pharmacology.

1. Wu DL, Ding ZH, Lu T*, Chen YD*, Zhang F*, Lu S*. DDR1-targeted therapies: current limitations and future potential [J]. Drug Discov. Today 2024, 29 (5), 103975.

2. Wang ZJ^#, Lu X^#, Liu CL^#, Liu CL, Huang F, Lu T, Chen YD*, Liu LF*, Lu S*. Discovery of FLT3-targeting PROTACs with potent antiproliferative activity against acute myeloid leukemia cells harboring FLT3 mutations [J]. Eur. J. Med. Chem. 2024, 268, 116237.

3. Wang ZJ^#, Wu DL^#, Zhao XF^#, Liu CL, Jia SM, He QD, Huang F, Cheng ZT, Lu T*, Chen YD*, Chen Y*, Yang P*, Lu S*. Rational discovery of dual FLT3/HDAC inhibitors as a potential AML therapy [J]. Eur. J. Med. Chem. 2023, 260, 115759.

4. He QD^#, Zhao XF^#, Wu DL, Jia SM, Liu CL, Cheng ZT, Huang F, Chen YD*, Lu T*, Lu S*. Hydrophobic tag-based protein degradation: development, opportunity and challenge [J]. Eur. J. Med. Chem. 2023, 260, 115741. DOI: 10.1016/j.ejmech.2023.115741  15 November 2023

5. Zhi YL, Li HM, Yang P, Jin QM, Yao C, Li BQ, Ling J, Guo H, Li TH, Jin JL, Wang Y*, Chen YD*, Lu T*, Lu S*. Rational design of 4-((6-phenoxypyrimidin-4-yl)amino)-N-(4-(piperazin-1-yl)phenyl)-1H-pyrazole-3-carboxamide (LT-540-717) as orally bioavailable FLT3 inhibitor [J]. Eur. J. Med. Chem. 2023, 256, 115448. 

6. Wang ZJ, Cai JH, Ren JW, Chen Y, Wu YL, Cheng J, Jia K, Huang F, Cheng ZT, Sheng TC, Song SY, Heng H, Zhu YF, Tang WF, Li HM*, Lu T*, Chen YD*, Lu S*. Discovery of a potent FLT3 inhibitor (LT-850-166) with capacity of overcoming a variety of FLT3 mutations. [J]. J. Med. Chem. 2021, 64 (19), 14664-14701. 

7. Wang ZJ, Cai JH, Cheng J, Yang WQZ, Zhu YF, Li HM, Lu T*, Chen YD*, Lu S*. FLT3 inhibitors in acute myeloid leukemia: challenges and recent developments in overcoming resistance [J]. J. Med. Chem. 2021, 64 (6), 2878-2900.

His research interests mainly focus on the discovery of the targeted drugs including FLT3 inhibitors, RIPK1 inhibitors, DDR1 inhibitors, etc.